Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 1
1948 2
1949 3
1950 5
1971 1
1973 2
1974 4
1979 1
1982 1
1983 1
1984 1
1985 1
1989 1
1990 2
1991 3
1992 1
1993 1
1994 1
1995 1
1996 3
1998 1
1999 1
2000 2
2001 2
2003 4
2004 2
2005 5
2006 1
2007 5
2008 3
2009 4
2010 2
2013 1
2014 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

70 results

Results by year

Filters applied: . Clear all
Page 1
Trial of Solanezumab in Preclinical Alzheimer's Disease.
Sperling RA, Donohue MC, Raman R, Rafii MS, Johnson K, Masters CL, van Dyck CH, Iwatsubo T, Marshall GA, Yaari R, Mancini M, Holdridge KC, Case M, Sims JR, Aisen PS; A4 Study Team. Sperling RA, et al. N Engl J Med. 2023 Sep 21;389(12):1096-1107. doi: 10.1056/NEJMoa2305032. Epub 2023 Jul 17. N Engl J Med. 2023. PMID: 37458272 Free PMC article. Clinical Trial.
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Salloway S, et al. N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839. N Engl J Med. 2014. PMID: 24450891 Free PMC article. Clinical Trial.
Isopropyl alcohol intoxication.
McCORD WM, SWITZER PK, BRILL HH Jr. McCORD WM, et al. Among authors: switzer pk. South Med J. 1948 Jul;41(7):639-42. doi: 10.1097/00007611-194807000-00013. South Med J. 1948. PMID: 18872279 No abstract available.
Olfactory function in apoE knockout mice.
Nathan BP, Yost J, Litherland MT, Struble RG, Switzer PV. Nathan BP, et al. Among authors: switzer pv. Behav Brain Res. 2004 Apr 2;150(1-2):1-7. doi: 10.1016/S0166-4328(03)00219-5. Behav Brain Res. 2004. PMID: 15033273
Delayed olfactory nerve regeneration in ApoE-deficient mice.
Nathan BP, Nisar R, Short J, Randall S, Grissom E, Griffin G, Switzer PV, Struble RG. Nathan BP, et al. Among authors: switzer pv. Brain Res. 2005 Apr 11;1041(1):87-94. doi: 10.1016/j.brainres.2005.02.011. Brain Res. 2005. PMID: 15804503
The Kiva project.
Cardona FA, Davis ER, Switzer PK 3rd. Cardona FA, et al. Among authors: switzer pk 3rd. J S C Med Assoc. 1996 May;92(5):220-4. J S C Med Assoc. 1996. PMID: 8691817
Mortality displacement and distributed lag models.
Roberts S, Switzer P. Roberts S, et al. Among authors: switzer p. Inhal Toxicol. 2004 Dec 15;16(14):879-88. doi: 10.1080/08958370490519598. Inhal Toxicol. 2004. PMID: 15764475
Challenges assessing clinical endpoints in early Huntington disease.
Paulsen JS, Wang C, Duff K, Barker R, Nance M, Beglinger L, Moser D, Williams JK, Simpson S, Langbehn D, van Kammen DP; PREDICT-HD Investigators of the Huntington Study Group. Paulsen JS, et al. Mov Disord. 2010 Nov 15;25(15):2595-603. doi: 10.1002/mds.23337. Mov Disord. 2010. PMID: 20623772 Free PMC article.
70 results